Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DN91RC
|
|||
| Drug Name |
IGM-2323
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C82-C85; ICD-9: 200, 202] | Phase 1 | [1] | |
| Company |
IGM Biosciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | Inhibitor | [2] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04082936) A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of IGM Biosciences. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.